Exact Sciences (EXAS) Tops Q1 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Exact Sciences Announces First Quarter 2022 Results
April 26, 2022 4:05 PM EDTTotal first quarter revenue of $487M, including Screening revenue of $307M, Precision Oncology revenue of $153M, and COVID-19 testing revenue of $27MTotal first quarter revenue, excluding COVID-19 testing, increased 24% compared to the first quarter of 2021, including 28% increase in Screening revenue and 18% increase in Precision Oncology revenueScreening revenue growth driven by improved sales team productivity, Cologuard rescreens, and Cologuard use in 45-49 age group
MADISON, Wis., April 26, 2022 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leader in... More
